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The role of DJOXWHQIUHHGLHWLQµOLIHVW\OHUV¶" The first double blind randomized study 
Rej A1, Kurien M1, Trott N1, Sanders D S1 
1Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching 
Hospital NHS Foundation Trust, Sheffield, S10 2JF 
 
Introduction: A gluten free diet (GFD) is essential in the management of coeliac disease, as 
well as several studies demonstrating its utility as a dietary therapy in patients with irritable 
bowel syndrome. The aim of this double-blind placebo controlled study was to assess the 
UROHRID*)'LQDKHDOWK\SRSXODWLRQZKRWDNHD*)'DVDOLIHVW\OHFKRLFHµOLIHVW\OHUV¶.  
Methods: Subjects were recruited via an advert, following exclusion criteria including coeliac 
disease. Following selection, subjects were commenced on a 2 week GFD following 
evaluation by a dietitian. Participants were then randomized to receive either organic gluten 
(Group A, Vital Gluten 14g gluten protein/day) or gluten free flour (Group B) in pre-made 
bags, over a 2 week period. These were sprinkled on their food twice daily. Gastrointestinal 
Symptom Rating Scale (GSRS) scores were assessed at baseline (following 2 weeks GFD) 
and after 2 weeks of randomization. Data was analyzed using SPSS version 22.  
Results:  45 subjects were identified with 28 participants recruited into the trial (Group A; 
n=14, Group B; n=14) following exclusion criteria. Median age was 36.5 years (range: 19-63) 
and 21 (75%) were female. There was no significant difference in baseline demographics 
between both groups (p=0.54). Over a 2 week period there was no significant difference in 
gastrointestinal symptoms or fatigue in either group, as seen in Table 1.  
  
 
 
Conclusion: This study demonstrates that gluten is unlikely to be the culprit agent for 
gastrointestinal symptoms or fatigue in healthy individuals.  A GFD has no evidence base in 
individuals who do not have coeliac disease or IBS. The public should be discouraged from 
considering a GFD of their own volition.  
Table 1
GSRS
Group A 
(Baseline)
Group A (End of 
Intervention)
Group B 
(Baseline)
Group B (End of 
Intervention)
Mean +/- SD Mean +/- SD
Difference from 
Baseline (Paired T-
test), p-value
Mean +/- SD Mean +/- SD
Difference from 
Baseline (Paired T-
test), p-value
Abdo Pain 2.50 +/- 1.40 2.14 +/- 1.70 0.504 2.35+/- 1.33 2.07+/- 0.99 0.486
Reflux 1.71 +/- 1.13 1.64 +/- 1.15 0.72 2.50 +/- 2.20 2.57 +/- 1.95 0.895
Indigestion 2.14 +/- 1.35 2.07 +/- 1.32 0.876 2.14 +/- 1.35 1.79 +/- 0.97 0.336
Diarrhoea 2.71 +/- 1.93 1.64 +/- 0.92 0.03 1.85 +/- 1.46 1.86 +/- 1.35 1
Constipation 2.50 +/- 1.82 2.46 +/- 1.81 0.697 1.92 +/- 1.54 2.50 +/- 1.65 0.179
Fatigue Score 6.61 +/- 2.36 6.00 +/-2.98 0.585 6.57 +/-2.44 5.36 +/-2.27 0.232
